Título / Title

ANTIANGIOGENIC TREATMENT IN MYOPIC MEMBRANES

Introdução / Purpose

Introduction: Myopia is one of the most common refractive errors and studies shows an increase in the prevalence around the globe. Choroidal neovascular membrane (CNVM) is a complication that occurs in 5-11% of pathological myopia (PM), despite it can occur in any degree of myopia with or without degenerative fundus change.. The aim of this study was to evaluate the response of myopic CNVM to treatment with either bevacizumab or ranibizumab treatment and analyze the results.

Material e Método / Methods

Methods: Retrospective analysis of 28 eyes of 28 patients diagnosed with myopic CNVM and treated with anti-VEGF therapy (bevacizumab and ranibizumab) between February 2014 and July 2017, with at least 6 month follow-up. SD-OCT was performed previously and during the follow-up time in all patient.

Resultados / Results

Results: Of the 28 studied eyes (28 patients), mean age was 41,4 years, with a predominance of females, degree of myopia varying from −3,00D to -16,50D (mean -7,54D). Symptoms varied from 7 days to 3 months (mean time: 3,5 weeks) and mean of best correct vision acuity (BCVA) prior to treatment was 20/100. SD-OCT and AF was performed in all patients and showed classic myopic CNVM in all eyes. Twenty eyes (71,42%) required only one injection and none recured after the end of the treatment. Improvement in 4 or more lines eas observed in 22 eyes (78,58%). No correlation was seen between age, degree of myopia or treatment but eraly treatment showed to be more effiective in the controll of the myopic membranes and final visual improvement.

Discussão e Conclusões / Conclusion

Conclusion: Ranibizumab and bevacizumab showed similar therapeutic and safety effects in the treatment of myopic membranes. Unlike AMD, the number of injections required is limited reducing the incidence of complications and with significant improvement of visual acuity. As there seems to be a relationship between onset of the symptoms, treatment and visual acuity improvement, efforts should be done to start anti-VEGF therapy as earlier as possible.

Palavras Chave

pathologic myopia, choroidal membranes (CNVM), anti-Vegf, treatment, blindness.

Area

CLINICAL RETINA